Latest Conference Articles

CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.

Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.

In this post-AAD interview, Cohen discusses his contribution to the presentation titled ‘Psoriasis: Modern Therapeutic Approaches.’

Join us April 01 on Twitter for a pre-meeting Tweet chat ahead of the American College of Cardiology's 2024 annual meeting!

New data suggest children with atopic dermatitis and comorbid ADHD are nearly 3 times more likely to struggle with memory compared to those with just ADHD.

In this post-AAD 2024 interview, Stein Gold commented on her team’s two recent sub-analyses of the phase 4 IMMpulse studies on risankizumab for psoriasis.

Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.

Isotretinoin was actually linked to a taller adult height among those who took it to treat acne in childhood versus doxycycline, in a new study.

In this AAD 2024 interview, Bunick highlights several new findings on the use of topical isotretinoin for treatment of congenital ichthyosis.

Alexis discusses clinical and demographic hurdles in treating skin of color for conditions like atopic dermatitis, and the potential of research like that being done in tapinarof cream 1%.

Blauvelt discusses the future research of higher-dose risankizumab for patients with psoriasis—and why it may be "disruptive in the treatment space."

Alexis spoke in this AAD interview about his team’s results regarding lebrikizumab for adults and adolescents with moderate-to-severe atopic dermatitis and skin of color.

New global data suggest children with moderate to severe atopic dermatitis may experience stunted growth due to the effect of their disease on sleep, as well as use of certain therapies.

Gelfand discusses the convenience of phototherapy, and how its efficacy may complement biologic regimens in patients with psoriasis.

These data presented at AAD 2024 highlight deuruxolitinib’s efficacy in the treatment of adults with moderate-to-severe alopecia areata.

New data from the Mayo Clinic show high BMI does not correlate with severe hidradenitis suppurativa in affected children and adolescents.

Another segment of Silverberg’s interview at AAD 2024 featured a discussion on safety data and the larger implications of these phase 3 findings for eczema management.

This interview at AAD featured a discussion with Silverberg on nemolizumab’s efficacy and safety at Week 48 among patients with moderate-to-severe atopic dermatitis.

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab.

These study findings, presented at AAD 2024, were the results of a recent analysis conducted to assess long-term outcomes among patients with psoriasis.

In this segment of his AAD interview, Hamzavi discussed more about his team’s findings on upadacitinib as well as their implications and future in terms of research.

In a phase 3 trial that featured approximately half of participants with skin of color, tapinarof cream 1.0% provided consistent benefit for patients identified as White, Black, or Asian.

Kim discusses the state of dermatology innovation and applied care, as well as his involvement in a new company in the space.

In this interview segment, Lebwohl discusses the implications of his team’s late-breaking data on bimekizumab for clinical practice.

In this interview at AAD 2024, Porter discussed her team’s phase 2 findings on hidradenitis suppurativa the impact of ruxolitinib cream among those with Hurley Stage I and II.

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

A secondary analysis from TRuE-AD3 shows ruxolitinib cream significantly benefits pediatric atopic dermatitis patient-reported outcomes.

This AAD 2024 interview features a discussion with Lebwohl on his team’s new late-breaking data, covering long-term findings on bimekizumab.